Please login to the form below

Not currently logged in
Email:
Password:

UCB admits Keppra misbranding offence

UCB is to pay $34m after admitting to off-label marketing of its epilepsy drug Keppra as a treatment for migraine

UCB has agreed to pay $34.4m to settle a dispute with the US Department of Justice regarding off-label marketing of its epilepsy drug Keppra.

The Belgian company's US subsidiary pleaded guilty to a single misdemeanour violation and entered into a separate civil settlement agreement to resolve allegations relating to misbranding of Keppra (levetiracetam) as a migraine treatment.

Greg Duncan, UCB's president for North American operations, said: "We have worked diligently over the years to enhance our compliance programme and we continue to evolve our compliance efforts to meet the changing demands of the regulatory environment in which we operate. We are pleased to have resolved this matter."

The events occurred more than six years ago, and UCB said it cooperated fully with the US authorities since learning of the investigation in 2008. It also signed a five-year corporate integrity agreement with the US Department of Health and Human Services.

13th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Innovation and agility
Start small but think big
Exploring the potential of agility in unlocking creativity...
The Pivot
In times of uncertainty it is critical for businesses to take action to protect their brand image and longevity....
Peter Jackson
The global antibiotic crisis: a 2020 perspective
A report from the CDC says the ‘approaching’ post-antibiotic era is already here...

Infographics